- Home
- HCM
as 04-18-2025 1:37pm EST
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
| Founded: | 2000 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.5B | IPO Year: | N/A |
| Target Price: | $19.00 | AVG Volume (30 days): | 128.4K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.04 | EPS Growth: | -66.28 |
| 52 Week Low/High: | $11.51 - $21.92 | Next Earning Date: | 03-19-2025 |
| Revenue: | $630,201,000 | Revenue Growth: | -24.80% |
| Revenue Growth (this year): | 28.98% | Revenue Growth (next year): | 20.41% |
Latest HUTCHMED (China) Limited News
HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Simply Wall St.
a month ago
HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
a month ago
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
GuruFocus.com
a month ago
HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...
GlobeNewswire
a month ago
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
GlobeNewswire
a month ago
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
GlobeNewswire
a month ago
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
Simply Wall St.
a month ago
HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years
Compare HCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCM HUTCHMED (China) Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.